TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders

Anagrelide is often used in the treatment of thrombocythemia in myeloproliferative disease (MPD), but information concerning effects of treatment on cytokines involved in regulation of blood platelet levels is limited. Here, we investigated serum levels of thrombopoietin (TPO) and soluble IL-6 recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmblad, Jan, Björkholm, Magnus, Kutti, Jack, Lärfars, Gerd, Löfvenberg, Eva, Markevärn, Berit, Merup, Mats, Mauritzson, Nils, Westin, Jan, Samuelsson, Jan, Birgegård, Gunnar
Formato: Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2008
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2293642/
https://www.ncbi.nlm.nih.gov/pubmed/18414650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2293642/
https://www.ncbi.nlm.nih.gov/pubmed/18414650

Ejemplares similares